- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- IPCA LABORATORIES LIMITED (pharmaceuticals)
- IPCA LABORATORIES LIMITED Financial Data
IPCA Labs Fact Sheet 
(IPLB)
Here is the latest financial fact sheet of IPCA Labs. For more details, see the IPCA Labs quarterly results and IPCA Labs share price and chart. For a sector overview, read our pharmaceuticals sector report.
IPCA LABS Price History
| % ch | % | -0.4 |
| No. of shares | m | 126.20 |
| % ch week | % | 1.9 |
| % ch 1-mth | % | 10.0 |
| % ch 12-mth | % | 53.8 |
| 52 week H/L | Rs | 768.0/400.0 |
IPCA LABS Financials
| No. of Mths Year Ending |
12 Mar-13* |
12 Mar-14* |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
5-Yr Chart Click to enlarge
|
|---|
| IPCA LABS EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 567 | 907 | 899 | 888 | 643 | |
| Low | Rs | 320 | 541 | 591 | 629 | 503 | |
| Sales per share (Unadj.) | Rs | 222.9 | 260.0 | 249.2 | 230.3 | 254.4 | |
| Earnings per share (Unadj.) | Rs | 25.6 | 37.9 | 20.1 | 7.6 | 16.1 | |
| Diluted earnings per share | Rs | 25.6 | 37.9 | 20.1 | 7.6 | 16.1 | |
| Cash flow per share (Unadj.) | Rs | 32.5 | 46.1 | 34.4 | 20.6 | 29.8 | |
| Dividends per share (Unadj.) | Rs | 4.00 | 5.00 | 1.00 | 0 | 1.00 | |
| Adj. dividends per share | Rs | 4.00 | 5.00 | 1.00 | 0.00 | 1.00 | |
| Dividend yield (eoy) | % | 0.9 | 0.7 | 0.1 | 0 | 0.2 | |
| Book value per share (Unadj.) | Rs | 123.1 | 155.3 | 174.1 | 179.0 | 194.6 | |
| Adj. book value per share | Rs | 123.1 | 155.3 | 174.1 | 179.0 | 194.6 | |
| Shares outstanding (eoy) | m | 126.20 | 126.20 | 126.20 | 126.20 | 126.20 | |
| Bonus/Rights/Conversions | ESOS | - | - | - | - | ||
| Price / Sales ratio | x | 2.0 | 2.8 | 3.0 | 3.3 | 2.3 | |
| Avg P/E ratio | x | 17.3 | 19.1 | 37.0 | 99.5 | 35.7 | |
| P/CF ratio (eoy) | x | 13.6 | 15.7 | 21.7 | 36.9 | 19.2 | |
| Price / Book Value ratio | x | 3.6 | 4.7 | 4.3 | 4.2 | 2.9 | |
| Dividend payout | % | 15.6 | 13.2 | 5.0 | 0 | 6.2 | |
| Avg Mkt Cap | Rs m | 55,970 | 91,356 | 94,057 | 95,723 | 72,300 | |
| No. of employees | `000 | 10.9 | 11.7 | 13.0 | 13.1 | 13.3 | |
| Total wages/salary | Rs m | 3,918 | 4,980 | 5,651 | 6,256 | 6,960 | |
| Avg. sales/employee | Rs Th | 2,578.7 | 2,798.5 | 2,416.4 | 2,213.3 | 2,413.5 | |
| Avg. wages/employee | Rs Th | 359.1 | 424.7 | 434.3 | 476.4 | 523.2 | |
| Avg. net profit/employee | Rs Th | 296.6 | 408.1 | 195.4 | 73.3 | 152.4 | |
| IPCA LABS INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 28,131 | 32,818 | 31,444 | 29,065 | 32,106 | |
| Other income | Rs m | 143 | 223 | 327 | 222 | 226 | |
| Total revenues | Rs m | 28,274 | 33,040 | 31,771 | 29,287 | 32,332 | |
| Gross profit | Rs m | 5,601 | 7,383 | 5,363 | 2,896 | 4,448 | |
| Depreciation | Rs m | 867 | 1,031 | 1,796 | 1,633 | 1,730 | |
| Interest | Rs m | 334 | 269 | 284 | 319 | 241 | |
| Profit before tax | Rs m | 4,543 | 6,306 | 3,611 | 1,166 | 2,703 | |
| Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | -8 | 3 | -49 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Tax | Rs m | 1,299 | 1,524 | 1,019 | 204 | 675 | |
| Profit after tax | Rs m | 3,236 | 4,785 | 2,542 | 962 | 2,028 | |
| Gross profit margin | % | 19.9 | 22.5 | 17.1 | 10.0 | 13.9 | |
| Effective tax rate | % | 28.6 | 24.2 | 28.2 | 17.5 | 25.0 | |
| Net profit margin | % | 11.5 | 14.6 | 8.1 | 3.3 | 6.3 | |
| IPCA LABS BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 13,972 | 16,014 | 19,348 | 16,219 | 17,340 | |
| Current liabilities | Rs m | 6,337 | 7,915 | 12,517 | 9,700 | 9,559 | |
| Net working cap to sales | % | 27.1 | 24.7 | 21.7 | 22.4 | 24.2 | |
| Current ratio | x | 2.2 | 2.0 | 1.5 | 1.7 | 1.8 | |
| Inventory Days | Days | 96 | 94 | 107 | 105 | 100 | |
| Debtors Days | Days | 54 | 50 | 73 | 56 | 57 | |
| Net fixed assets | Rs m | 12,098 | 14,841 | 20,540 | 21,429 | 20,779 | |
| Share capital | Rs m | 252 | 252 | 252 | 252 | 252 | |
| "Free" reserves | Rs m | 15,051 | 19,098 | 21,564 | 22,578 | 24,499 | |
| Net worth | Rs m | 15,538 | 19,597 | 21,965 | 22,592 | 24,553 | |
| Long term debt | Rs m | 3,662 | 2,940 | 4,987 | 4,843 | 3,517 | |
| Total assets | Rs m | 26,970 | 32,106 | 41,248 | 38,917 | 39,595 | |
| Interest coverage | x | 14.6 | 24.5 | 13.7 | 4.7 | 12.2 | |
| Debt to equity ratio | x | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | |
| Sales to assets ratio | x | 1.0 | 1.0 | 0.8 | 0.7 | 0.8 | |
| Return on assets | % | 13.2 | 15.7 | 6.9 | 3.3 | 5.7 | |
| Return on equity | % | 20.8 | 24.4 | 11.6 | 4.3 | 8.3 | |
| Return on capital | % | 25.4 | 29.2 | 14.3 | 5.4 | 10.5 | |
| Exports to sales | % | 59.2 | 60.4 | 52.9 | 49.2 | 48.6 | |
| Imports to sales | % | 15.0 | 16.1 | 16.7 | 15.3 | 14.2 | |
| Exports (fob) | Rs m | 16,667 | 19,836 | 16,624 | 14,299 | 15,617 | |
| Imports (cif) | Rs m | 4,221 | 5,282 | 5,247 | 4,445 | 4,571 | |
| Fx inflow | Rs m | 16,766 | 20,048 | 16,749 | 14,299 | 15,617 | |
| Fx outflow | Rs m | 5,804 | 7,272 | 6,956 | 5,822 | 5,828 | |
| Net fx | Rs m | 10,962 | 12,776 | 9,793 | 8,477 | 9,790 | |
| IPCA LABS CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 3,888 | 5,223 | 4,682 | 7,087 | 2,764 | |
| From Investments | Rs m | -2,599 | -3,690 | -6,893 | -2,183 | -1,432 | |
| From Financial Activity | Rs m | -829 | -1,361 | 2,505 | -4,615 | -1,591 | |
| Net Cashflow | Rs m | 460 | 172 | 294 | 288 | -259 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: Premchand Godha (MD) | COMP SEC: Harish P. Kamath (VP - Legal) | YEAR OF INC: 1949 | BSE CODE: 524494 | FV (Rs): 2 | DIV YIELD (%): 0.1 |
More Pharmaceuticals Company Fact Sheets: SUVEN LIFE PLETHICO PHARMA J.B.CHEMICALS VENUS REMEDIES PIRAMAL ENTERPRISES
Compare IPCA LABS With: SUVEN LIFE PLETHICO PHARMA J.B.CHEMICALS VENUS REMEDIES PIRAMAL ENTERPRISES
Compare IPCA LABS With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends Lower; Tata Steel & Vedanta Top Losers(Closing)
Indian share markets erased early gains to end lower today, as the opposition parties tabled a no-confidence motion against Prime Minister Narendra Modi's government.
Views on news
IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6% (Quarterly Result Update)
May 30, 2018 | Updated on May 30, 2018For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)
Feb 2, 2018Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)
Jul 12, 2018Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.
The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)
Jul 10, 2018If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...
The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)
Jul 11, 2018The price signals that MSP sends out, creates its own set of problems.
New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)
Jul 6, 2018ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.
When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)
Jul 6, 2018Buy Companies that can fight all kinds of Pandas and Bears in the long run.
More|
| |
TRACK IPCA LABS
- Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON IPCA LABS
IPCA LABS 8-QTR ANALYSIS
COMPARE IPCA LABS WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.